Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (COVID-19 Vaccine (ChAdOx1-S [recombinant]))
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- COVID-19 Vaccine (ChAdOx1-S [recombinant])
- Company
- AstraZeneca AB
- Status
- Withdrawn
- Therapeutic area
- COVID-19 virus infection
- CHMP opinion
- Fri 29 Jan 2021
- EU approval
- Fri 29 Jan 2021
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005675
- ATC
- J07BN02
- Official record
- www.ema.europa.eu
Indication
Vaxzevria is indicated for active immunisation to prevent COVID 19 caused by SARS CoV 2, in individuals 18 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.